Vilkligė klinikiniai tyrimai Misūris
8 tyrimai dėl Vilkligė ieško dalyvių vietose Misūris.
Miestai Misūris
Oficialus tyrimo tekstas (anglų kalba)
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50682, Kansas City
Renkami dalyviai3 fazė
Amžius 16 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06617325A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Kansas City
Renkami dalyviai3 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07430306Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- University Health Truman Medical Center, Kansas City
- ir dar 6
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-23 · NCT03816345Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
- Research Site, St Louis
Renkami dalyviai1 fazė
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-09-18 · NCT07201558A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Research Site, St Louis
Renkami dalyviai1/2 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-09-10 · NCT06897930A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- Washington University School of Medicine, St Louis
Renkami dalyviai1 fazė
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-08-28 · NCT06925542A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
- Investigative Site, Saint Joseph
Renkami dalyviai2 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-07-27 · NCT07260877Lupus Landmark Study: A Prospective Registry and Biorepository
- Washington University, St Louis
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 110 · Visoms lytims · Atnaujinta 2026-04-15 · NCT05934149Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.